Decision
UK plans to update legal definitions for gene therapy medicines
The UK plans to update legal definitions for gene therapy medicines to include synthetic materials and new genome editing technologies.
If you develop or manufacture gene therapies, the UK government plans to update how these medicines are defined under the Human Medicines Regulations 2012. Following a consultation, the MHRA and the Department of Health in Northern Ireland intend to introduce new legislation to include synthetic genetic materials and new genome editing technologies that do not fit current definitions.
The goal is to provide clearer rules for developers of advanced therapies, such as those used for cancer and genetic disorders, by ensuring synthetic products and modern gene editing are properly covered by the regulatory framework.
What we do not know: the specific timeline for when the new secondary legislation will come into force and the exact technical wording of the final revised definitions.
Headlines and summaries are written by AI for Outer News (RS Elite Pro s.r.o.) from the official text and are not reviewed by a person. They are not the official text and can contain mistakes: before you rely on one, read the original.
Original title: Consultation on the regulation of Gene therapy medicinal products
Read the official decisionSource: UK Government (GOV.UK) · Contains public sector information licensed under the Open Government Licence v3.0.